Skip Navigation

Cardiovascular Research 1999 41(1):65-76; doi:10.1016/S0008-6363(98)00266-1
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hayward, R.
Right arrow Articles by Lefer, A. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayward, R.
Right arrow Articles by Lefer, A. M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats

Reid Hayward, Barry Campbell, Yong K Shin, Rosario Scalia and Allan M Lefer*

Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

* Corresponding author. Tel.: +215-503-7760; fax: +215-503-2073.

Objective: Neutrophils (PMNs) contribute importantly to the tissue injury associated with ischemia and subsequent reperfusion of a vascular bed. The effects of a recombinant soluble human form of P-selectin glycoprotein ligand-1 (rsPSGL.Ig) on PMN–endothelial cell interactions were investigated in a well established model of feline myocardial-ischemia reperfusion injury. Methods: Cats were subjected to 90 min of myocardial ischemia followed by 270 min of reperfusion. Results: Administration of rsPSGL.Ig (1 mg/kg) just prior to reperfusion resulted in a significant reduction in myocardial necrosis compared to that in cats administered a low affinity mutant form of rsPSGL.Ig (1 mg/kg) (16±3 vs. 42±7% of area-at-risk, P<0.01). Cardioprotective effects were confirmed by significant (P<0.05) reductions in plasma creatine kinase activity in cats treated with rsPSGL.Ig. Inhibition of PMN–endothelial cell interactions was evidenced by a significant attenuation in cardiac myeloperoxidase activity (P<0.01) and reduced PMN adherence to ischemic–reperfused coronary endothelium (P<0.001). In addition, rsPSGL.Ig treatment significantly (P<0.01) preserved endothelium-dependent vasorelaxation in ischemic–reperfused coronary arteries. Conclusion: These results demonstrate that the administration of a recombinant soluble PSGL-1 reduces myocardial reperfusion injury and preserves vascular endothelial function, which is largely the result of reduced PMN–endothelial cell interactions.

KEYWORDS Cat; Cardiac necrosis; Creatine kinase activity; Endothelial function; Myeloperoxidase activity; Neutrophil adherence


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
J. M. van Gils, J. J. Zwaginga, and P. L. Hordijk
Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases
J. Leukoc. Biol., February 1, 2009; 85(2): 195 - 204.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.